Skip to main content

Table 2 Association between CIN-1-month and overall survival in patients with metastatic colorectal cancer receiving TAS-102

From: Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

Sample or stratum HR (95 % CI)a P-value
Overall 0.22 (0.12–0.38) < 0.0001
Strata   
 Men 0.15 (0.06–0.33) < 0.0001
 Women 0.31 (0.13–0.67) 0.0023
 Rectal 0.36 (0.15–0.78) 0.0092
 Colon 0.15 (0.06–0.34) < 0.0001
 RAS-mutant 0.32 (0.15–0.64) 0.001
 RAS-wild type 0.14 (0.05–0.35) < 0.0001
 Older adults (age > 65 years) 0.19 (0.09–0.40) < 0.0001
 Younger adults (age ≤ 65 years) 0.21 (0.07–0.52) 0.0003
 Higher Baseline CEA (> 55 ng/ml) 0.26 (0.11–0.56) 0.0004
 Lower Baseline CEA (≤ 55 ng/ml) 0.18 (0.07–0.42) < 0.0001
 Higher Baseline Neutrophil Count (> 4300/mm3) 0.25 (0.08–0.57) 0.0005
 Lower Baseline Neutrophil Count (≤ 4300/mm3) 0.27 (0.11–0.65) 0.0035
Absolute Neutrophil cutoff at 1-month   
 CIN-1-month (< 1000/mm3) 0.34 (0.16–0.66) 0.0008
 CIN-1-month (< 1500/mm3) 0.22 (0.12–0.38) < 0.0001
 CIN-1-month (< 2000/mm3) 0.28 (0.17–0.47) < 0.0001
 CIN-1-month (< 2500/mm3) 0.25 (0.16–0.42) < 0.0001
 CIN-1-month (< 3000/mm3) 0.26 (0.16–0.43) < 0.0001
  1. aHR for overall survival was calculated through Cox proportional hazards models